AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China • MC Services corporate website
22 Dec AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China